Laura M. Walker

This paper describes VYD222, a broadly neutralizing antibody effective against SARS-CoV-2 variants, including Omicron, and explains its structural basis for resistance to viral escape.

This paper predicts SARS-CoV-2 RBD evolution using deep mutational scanning to identify broadly neutralizing antibodies effective against existing and prospective variants.

The paper identifies conserved sites on influenza H1 and H3 hemagglutinin recognized by human antibodies and characterizes their neutralization potential and escape pathways.

The paper identifies non-neutralizing antibodies from CCHFV survivors that target multiple regions on GP38, showing protective efficacy in rodent models.

This study identifies infection-enhancing antibodies targeting the N-terminal domain of SARS-CoV-2 spike protein, which persist in convalescent patients and may be counteracted by viral mutations.

This study characterizes the serological repertoire of SARS-CoV-2 convalescent patients, revealing a high prevalence of iso-RBD antibodies that do not recognize prefusion-stabilized S, and shows that vaccination with prefusion-stabilized S reduces their prevalence.